insulin and glp-1 agonist combination of basal receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? | Diabetology & Metabolic Syndrome Is Toujeo a GLP-1? The
Description
95% CI 0.35, 3.14)
Are you a candidate?
Eli Lilly, makers of weight loss injection Zepbound, could soon be making its GLP-1 drug in pill form.
The primary outcome was the new onset of adverse CVEs, including heart failure, composite incidence of major adverse cardiovascular events (MACE
Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity
are the major companies operating in this market.
